Definium Therapeutics (DFTX) Shares Outstanding (Weighted Average) (2019 - 2026)

Definium Therapeutics (DFTX) has 8 years of Shares Outstanding (Weighted Average) data on file, last reported at $100.2 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 17.8% year-over-year to $100.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100.2 million (up 17.8% YoY) and the FY2025 annual result came in at $89.3 million, up 26.78% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $100.2 million in Q1 2026 per DFTX's latest filing, from $4.2 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $100.2 million in Q1 2026 and bottomed at $4.2 million in Q4 2025.
• The 5-year median for Shares Outstanding (Weighted Average) is $39.2 million (2023), against an average of $51.0 million.
• Peak annual rise in Shares Outstanding (Weighted Average) reached 11495.97% in 2022, while the deepest fall reached 95.18% in 2022.
• Tracing DFTX's Shares Outstanding (Weighted Average) over 5 years: stood at $30.9 million in 2022, then grew by 26.9% to $39.2 million in 2023, then surged by 79.94% to $70.5 million in 2024, then plunged by 94.04% to $4.2 million in 2025, then jumped by 2285.9% to $100.2 million in 2026.
• Per Business Quant, the three latest DFTX Shares Outstanding (Weighted Average) figures stand at $100.2 million (Q1 2026), $4.2 million (Q4 2025), and $85.9 million (Q3 2025).

Peer Comparison